Key result
Elevated serum uric acid levels (>7 mg/dl) were significantly associated with higher mortality (17 deaths vs 1 death, p<0.0001) and longer hospital stays in patients with decompensated chronic heart failure.
Why the study?
Traditional chronic heart failure biomarkers are costly and not universally accessible, creating a need for affordable and accessible prognostic alternatives.
Does elevated serum uric acid predict worse clinical outcomes in patients with decompensated chronic heart failure?
Population
126 patients with decompensated CHF
Comparison
Serum uric acid >7 mg/dl vs ≤7 mg/dl
Authors
Loading...
May support low-cost uric acid monitoring for risk stratification in decompensated CHF; leaves open incremental value over established biomarkers.
Observational (n=126)
No
Does elevated serum uric acid predict worse clinical outcomes in patients with decompensated chronic heart failure?
Absolute Event Rate: 27% vs 1.6%
p-value: p=<0.0001
Elevated serum uric acid (>7 mg/dl) is a low-cost, accessible prognostic biomarker associated with increased mortality and prolonged hospitalization in patients with decompensated chronic heart failure.
Priyadarshi et al. (2024) conducted an observational in Decompensated chronic heart failure (n=126). High serum uric acid levels (>7 mg/dl) vs. Low serum uric acid levels (≤7 mg/dl) was evaluated on Mortality (p=<0.0001). Elevated serum uric acid levels (>7 mg/dl) were significantly associated with higher mortality (17 deaths vs 1 death, p<0.0001) and longer hospital stays in patients with decompensated chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: